Blood Amyloid-Beta Relationship With Amyloid Plaques and CSF Amyloid-Beta
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,122
- 试验地点
- 1
- 主要终点
- Plasma amyloid-beta 42/40 ratio
研究概览
简要总结
The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.
详细描述
Alzheimer's disease is the most common cause of dementia and currently has no disease-modifying treatments or simple, accurate diagnostic tests. Amyloid beta builds up in the brain and forms plaques in people with Alzheimer's disease, and the buildup of this protein is found decades before symptoms of dementia begin. A blood test may be able to quickly and inexpensively screen people for Alzheimer's disease clinical trials and eventually diagnose Alzheimer's disease in the clinic.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 60 years of age
排除标准
- •Unable to perform one or more activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment or dependent on others due to cognitive impairment.
- •Body weight of <100 pounds
- •Active infectious disease (e.g., HIV, hepatitis B, hepatitis C)
- •Bleeding disorder
- •Taking an experimental drug for AD
- •Blood donation in the last two months
- •Blood transfusion in the last three months
结局指标
主要结局
Plasma amyloid-beta 42/40 ratio
时间窗: 6 months
Area under the curve (AUC) of the blood test (plasma amyloid-beta 42/40 ratio) in predicting amyloid PET status
时间窗: 6 months
次要结局
- Coefficient of variation for the initial and confirmatory blood amyloid-beta test results(6 months)